New medicines for four rare diseases – Tyrosinemia Type 1, Gaucher’s Disease, Wilson’s Disease, and Dravet-Lennox Gastaut Syndrome – are set to significantly reduce treatment costs, offering relief to many patients. The cost reduction, estimated at 100 times less, is attributed to the manufacturing of these new medications. This development is expected to alleviate financial burdens on patients suffering from these rare conditions. The specific details of the cost reduction and the manufacturing processes for these medicines were not provided in the summary. Nonetheless, the overall impact is a positive step towards making treatment more accessible for individuals facing these rare diseases. By Coshorts
Tap for more at Timesofindia
